The Drug Enforcement Administration (DEA) has selected participants Hear about the Trump administration’s cannabis reorganization process this will begin this month—and only those opposed to the reform have been invited to participate.
On Thursday, the DEA began notifying parties who expressed their intention to participate that they had been invited to participate, and sending rejection letters to those who were not invited.
The invited participants are:
- Drug and Alcohol Screening Association (NDASA)
- Tennessee Bureau of Investigation
- Smart Approaches to Marijuana (SAM)
- The states of Nebraska, Idaho, Indiana and Louisiana
- Voice of the Victims
- Kenneth Finn, MD
- Phillip A. Drum, PharmD
All organizations, individuals and officials have come out against marijuana reform, and some have filed lawsuits specifically trying to block cannabis reform.
Supporters of the reform who have expressed their intention to participate have not been invited.
According to several rejection letters seen by Marijuana Moment from cannabis reform advocates, the DEA said they do not meet the definition of “interested person” to participate because they “would not be harmed or harmed by any rule or proposed rule that may be issued.”
In a letter to the Drug Policy Alliance (DPA), DEA Administrator Terrance Cole wrote that the agency has “concluded that you have not demonstrated that you are harmed or harmed by the promulgation of a proposed rule to transfer marijuana, 21 CFR 1308.11(d)(23) 21 CFR 1308.11(d)(23), marijuana as defined in abstracts, 21 CFR. 1308.11(d)(58), and naturally derived delta-9-tetrahydrocannabinols from Schedules I through III of the CSA as proposed in the “Notice of Proposed Rulemaking” (NPRM).
“In fact, you state that the DPA supports the removal of marijuana from Schedule I and ‘does not object’ to the transfer of marijuana to Schedule III. Furthermore, the DPA states that any harm it would suffer from the NPRM would be to schedule marijuana in Schedule III. Because the DPA has not sufficiently demonstrated that the proposed rule itself is harmed or harmed, the DEA concludes that the DPA is not an “interested person.”
“Accordingly, the DEA is denying your request to participate in the hearing,” Cole told DPA.
Cat Packer, DPA’s director of drug markets and law enforcement, told Marihuana Moment after receiving the opt-out notice that “the rescheduling would leave the federal criminalization of marijuana largely intact and falls far short of what the public has asked for.”
“More than 70 percent of this public comments submitted on the proposed rule supported decriminalizationHowever, many patients, consumers, families, small businesses and individuals who have suffered the consequences of the ban — including arrests, incarcerations, family separations, housing barriers, immigration consequences and lost economic opportunities — have been excluded from meaningful participation in these proceedings, he said. dialogue, helping to shape the policies that affect their lives, families and communities.”
Michael Bronstein, president of the American Trade Association for Cannabis and Hemp (ATACH), said his group is “very disappointed” that not a single supporter of cannabis rescheduling was elected.
“The upcoming redistricting hearings will strictly include prohibitionist parties who oppose President Trump’s stance on redistricting. Now it’s up to the Drug Enforcement Administration to defend its rule,” he said.
SAM president Kevin Sabet, meanwhile, said his prohibitionist group “appreciates the opportunity to make our case” at the hearing.
“Rescheduling marijuana would be the biggest drug policy mistake in a generation,” he argued in a statement. “SAM looks forward to presenting the science, data, and public health stakes that show why reprogramming should be rejected.”
The hearingwhich will be overseen by a DEA administrative law judge, will begin on June 29 and conclude no later than July 15.
Acting Attorney General Todd Blanche in April He issued an order that immediately reclassified the state’s licensed medical cannabisas well as marijuana products approved by the Food and Drug Administration (FDA) under Schedule I through Schedule III of the Controlled Substances Act (CSA).
According to a separate order signed by the acting Attorney General, in the upcoming hearing, marijuana III.
In order to be considered for participation in the hearing, the parties had to submit requests, indicating their interest in the procedure, the claims or issues they want to hear and their position on these issues.
“The purpose of the hearing is to ‘receive factual evidence and expert opinion’ on whether marijuana should be transferred to Schedule III of the controlled substance list,” Blanche’s initial statement in April said.
The attorney general will also select an administrative law judge (ALJ) to oversee the proceeding.
“The ALJ’s authority includes the power to hold conferences to simplify or determine the issues at the hearing or to consider other matters that may assist in the expeditious resolution of the hearing; to require the parties to state their position in writing; to sign and issue subpoenas; to compel the production of documents and materials to the extent necessary to conduct the hearing; to examine witnesses; to direct, exclude, or testify; the Rule on Procedural Matters and the President’s DEA Hearing Procedures and Administrative Procedure Actions allowed under the law, Blanch wrote.
Preliminary hearing process on the marijuana redistricting process initiated by the Biden administration It was halted last year amid allegations of improper communications and witness selection.
the current The marijuana redistricting process is being challenged in several ways which have been upheld by a federal Court of Appeals. those pieces of State attorneys general have filed lawsuits against cannabis reform, Opponents of marijuana legalization and a a cannabis-based biopharmaceutical corporation.
Meanwhile, the reorganization of state-licensed medical cannabis is already having a major impact.
The Congressional Research Service published a report on the current rescheduling of cannabis Certified patients with medical marijuana from state licensed dispensaries are now eligible for Class III. “The order appears to allow end users to use marijuana medically without a CSA prescription,” he says.
The Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) has published a Draft update to a gun purchase form to recognize the legal status of medical marijuana in the reprogramming. The revised section of the question states that only the “recreational use or possession of marijuana” is federally prohibited, omitting the prior form’s mention of medical cannabis.
The US Treasury and Internal Revenue Service (IRS) said they plan to issued new tax guidelines for the marijuana industry after reprogramming. The reform will benefit state-licensed marijuana businesses by allowing them to take federal tax deductions that are currently prohibited under IRS Code Section III, known as Section 280E.
Even the DEA, which has long opposed cannabis legalization and accused the Biden administration of stalling the initiative in the reorganization process, has done so. It launched a registration process for legal marijuana businesses in the state to take advantage of the federal benefits that come with the reform.
The Department of Transport, on the other hand, issued guidelines stating this use Legal medical cannabis in the state is still no excuse for truck drivers to test positive for drugspilots and other safety-sensitive personnel.
A congressional committee recently Federal officials voted to block further steps to reschedule cannabis.
Read DEA Reorganization Denial the letter To the Drug Policy Alliance below: